In severe thyroid eye disease, lanreotide significantly improved ophthalmopathy in both eyes of four patients and one eye of one patient.
In plain wordsIn severe thyroid eye disease, lanreotide improved both eyes in four patients and one eye in one patient after treatment.
- Peptide
- Lanreotide
- Outcome
- DecreaseOphthalmopathy score (NOSPECS and clinical activity)
- Study
n = 5
- Outcome group
- Vision and retina · Eye
- Studied dose
- 0.04 g once every 2 weeks · intramuscular · 3 monthsAs given in this study (human).
Measurements
- Patients with significant improvement in both eyes
- 4 patients
- lanreotide group, 3 months
- Patients with significant improvement in one eye
- 1 patients
- lanreotide group, 3 months
Source sentences
After 3 months of treatment with LRT, four patients showed a statistically significant improvement in ophthalmopathy in both eyes and one in one eye.
3 context sentences(design, population, supporting numbers)
Five patients, three males and two females, mean age 50.6 +/- 7.6 S.D. (45-64) years, all with severe symptoms of TED were studied.
The five patients who comprised the treatment group received 0.04 g LRT i.m. once every 2 weeks over a period of 3 months, after which the Octreoscan-111 was repeated.
The control patients were given an injection of water i.m., also once every 2 weeks for 3 months, after which they were evaluated clinically.